Cargando…
Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
OBJECTIVES: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic pa...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519951/ https://www.ncbi.nlm.nih.gov/pubmed/33005417 http://dx.doi.org/10.1002/cti2.1182 |
_version_ | 1783587676280061952 |
---|---|
author | Jiang, Chuanhao Wang, Yali Hu, Min Wen, Lingjun Wen, Chuan Wang, Yang Zhu, Weihong Tai, Shi Jiang, Zhongbiao Xiao, Kui Faria, Nuno Rodrigues De Clercq, Erik Xu, Junmei Li, Guangdi |
author_facet | Jiang, Chuanhao Wang, Yali Hu, Min Wen, Lingjun Wen, Chuan Wang, Yang Zhu, Weihong Tai, Shi Jiang, Zhongbiao Xiao, Kui Faria, Nuno Rodrigues De Clercq, Erik Xu, Junmei Li, Guangdi |
author_sort | Jiang, Chuanhao |
collection | PubMed |
description | OBJECTIVES: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic patients infected with SARS‐CoV‐2. METHODS: We collected clinical, laboratory and epidemiological records of patients hospitalised in a coronavirus field hospital in Wuhan. We performed qualitative detection of anti‐SARS‐CoV‐2 immunoglobulin M (IgM) and immunoglobulin G (IgG) using archived blood samples. RESULTS: Of 214 patients with SARS‐CoV‐2, 26 (12%) were asymptomatic at hospital admission and during hospitalisation. Most asymptomatic patients were ≤ 60 years (96%) and females (65%) and had few comorbidities (< 16%). Serum levels of white and red blood cells were higher in asymptomatic than in symptomatic patients (P‐values < 0.05). During hospitalisation, IgG seroconversion was commonly observed in both asymptomatic and symptomatic patients (85% versus 94%, P‐value = 0.07); in contrast, IgM seroconversion was less common in asymptomatic than in symptomatic patients (31% versus 74%, P‐value < 0.001). The median time from the first virus‐positive screening to IgG or IgM seroconversion was significantly shorter in asymptomatic than in symptomatic patients (median: 7 versus 14 days, P‐value < 0.01). Furthermore, IgG/IgM seroconversion rates increased concomitantly with the clearance of SARS‐CoV‐2 in both asymptomatic and symptomatic patients. At the time of virus clearance, IgG/IgM titres and plasma neutralisation capacity were significantly lower in recovered asymptomatic than in recovered symptomatic patients (P‐values < 0.01). CONCLUSION: Asymptomatic and symptomatic patients exhibited different kinetics of IgG/IgM responses to SARS‐CoV‐2. Asymptomatic patients may transmit SARS‐CoV‐2, highlighting the importance of early diagnosis and treatment. |
format | Online Article Text |
id | pubmed-7519951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75199512020-09-30 Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Jiang, Chuanhao Wang, Yali Hu, Min Wen, Lingjun Wen, Chuan Wang, Yang Zhu, Weihong Tai, Shi Jiang, Zhongbiao Xiao, Kui Faria, Nuno Rodrigues De Clercq, Erik Xu, Junmei Li, Guangdi Clin Transl Immunology Original Article OBJECTIVES: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic patients infected with SARS‐CoV‐2. METHODS: We collected clinical, laboratory and epidemiological records of patients hospitalised in a coronavirus field hospital in Wuhan. We performed qualitative detection of anti‐SARS‐CoV‐2 immunoglobulin M (IgM) and immunoglobulin G (IgG) using archived blood samples. RESULTS: Of 214 patients with SARS‐CoV‐2, 26 (12%) were asymptomatic at hospital admission and during hospitalisation. Most asymptomatic patients were ≤ 60 years (96%) and females (65%) and had few comorbidities (< 16%). Serum levels of white and red blood cells were higher in asymptomatic than in symptomatic patients (P‐values < 0.05). During hospitalisation, IgG seroconversion was commonly observed in both asymptomatic and symptomatic patients (85% versus 94%, P‐value = 0.07); in contrast, IgM seroconversion was less common in asymptomatic than in symptomatic patients (31% versus 74%, P‐value < 0.001). The median time from the first virus‐positive screening to IgG or IgM seroconversion was significantly shorter in asymptomatic than in symptomatic patients (median: 7 versus 14 days, P‐value < 0.01). Furthermore, IgG/IgM seroconversion rates increased concomitantly with the clearance of SARS‐CoV‐2 in both asymptomatic and symptomatic patients. At the time of virus clearance, IgG/IgM titres and plasma neutralisation capacity were significantly lower in recovered asymptomatic than in recovered symptomatic patients (P‐values < 0.01). CONCLUSION: Asymptomatic and symptomatic patients exhibited different kinetics of IgG/IgM responses to SARS‐CoV‐2. Asymptomatic patients may transmit SARS‐CoV‐2, highlighting the importance of early diagnosis and treatment. John Wiley and Sons Inc. 2020-09-26 /pmc/articles/PMC7519951/ /pubmed/33005417 http://dx.doi.org/10.1002/cti2.1182 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jiang, Chuanhao Wang, Yali Hu, Min Wen, Lingjun Wen, Chuan Wang, Yang Zhu, Weihong Tai, Shi Jiang, Zhongbiao Xiao, Kui Faria, Nuno Rodrigues De Clercq, Erik Xu, Junmei Li, Guangdi Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) |
title | Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) |
title_full | Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) |
title_fullStr | Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) |
title_full_unstemmed | Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) |
title_short | Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) |
title_sort | antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (sars‐cov‐2) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519951/ https://www.ncbi.nlm.nih.gov/pubmed/33005417 http://dx.doi.org/10.1002/cti2.1182 |
work_keys_str_mv | AT jiangchuanhao antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT wangyali antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT humin antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT wenlingjun antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT wenchuan antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT wangyang antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT zhuweihong antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT taishi antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT jiangzhongbiao antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT xiaokui antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT farianunorodrigues antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT declercqerik antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT xujunmei antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 AT liguangdi antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2 |